Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Expected to Announce Quarterly Sales of $8.31 Million

Wall Street brokerages expect Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Rating) to report $8.31 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Alpine Immune Sciences’ earnings. The highest sales estimate is $15.33 million and the lowest is $4.60 million. Alpine Immune Sciences reported sales of $7.19 million in the same quarter last year, which would suggest a positive year over year growth rate of 15.6%. The business is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Alpine Immune Sciences will report full-year sales of $66.15 million for the current year, with estimates ranging from $37.00 million to $102.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $40.07 million, with estimates ranging from $32.00 million to $45.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.06). Alpine Immune Sciences had a negative net margin of 139.41% and a negative return on equity of 46.87%.

Several brokerages have recently commented on ALPN. Zacks Investment Research lowered Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, March 22nd. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Alpine Immune Sciences in a research report on Friday, May 13th. Oppenheimer dropped their price objective on Alpine Immune Sciences from $19.00 to $17.00 in a research report on Monday, March 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Alpine Immune Sciences in a research report on Tuesday.

Shares of Alpine Immune Sciences stock opened at $7.95 on Thursday. The firm has a market cap of $241.11 million, a P/E ratio of -4.47 and a beta of 1.74. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02. Alpine Immune Sciences has a 12 month low of $6.00 and a 12 month high of $15.14. The stock’s fifty day moving average price is $8.58 and its 200-day moving average price is $9.94.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Ensign Peak Advisors Inc boosted its holdings in Alpine Immune Sciences by 50.9% in the first quarter. Ensign Peak Advisors Inc now owns 110,017 shares of the biotechnology company’s stock worth $987,000 after acquiring an additional 37,087 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Alpine Immune Sciences by 70.8% in the first quarter. Goldman Sachs Group Inc. now owns 22,850 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 9,471 shares in the last quarter. State Street Corp boosted its holdings in Alpine Immune Sciences by 7.1% in the first quarter. State Street Corp now owns 220,621 shares of the biotechnology company’s stock worth $1,979,000 after acquiring an additional 14,609 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new stake in Alpine Immune Sciences in the first quarter worth about $3,016,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Alpine Immune Sciences in the first quarter worth about $37,546,000. 77.00% of the stock is owned by institutional investors and hedge funds.

About Alpine Immune Sciences (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Featured Stories

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.